Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2016 | Why drug combinations are the future of treatment in CLL

Paolo Ghia • 9 Jun 2016
EHA 2016
Chronic Lymphocytic Leukemia Ibrutinib Obinutuzumab Venetoclax

Paolo Ghia, MD, PhD from the San Raffaele Scientific Institute, Milan, Italy discusses drug combinations for the treatment of chronic lymphocytic leukemia (CLL). In particular, Dr Ghia talks about the combination of ibrutinib and venetoclax, as well as ibrutinib and venetoclax in combination with obinutuzumab (GA-101) (NCT02758665).
Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.

More from Paolo Ghia

Nemtabrutinib plus venetoclax in R/R CLL: dose escalation and confirmation in the BELLWAVE-010 trial
1:57
Nemtabrutinib plus venetoclax in R/R CLL: dose escalation and confirmation in the BELLWAVE-010 trial
Paolo Ghia • 8 Dec 2025
Treatment options for patients with CLL who have developed resistance to covalent BTK inhibitors
1:15
Treatment options for patients with CLL who have developed resistance to covalent BTK inhibitors
Paolo Ghia • 8 Dec 2025
Updates to the ESMO CLL clinical practice guidelines: implications for relapsed disease
19:55
Updates to the ESMO CLL clinical practice guidelines: implications for relapsed disease
Paolo Ghia • 25 Apr 2025
A study investigating the efficacy of CAR-T therapy in Richter's transformation
1:52
A study investigating the efficacy of CAR-T therapy in Richter's transformation
Paolo Ghia • 27 Sep 2024

Related Videos

Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Paolo Ghia • 6 Dec 2025
Translating academic-center data to community settings to improve the adoption of bispecifics
1:54
Translating academic-center data to community settings to improve the adoption of bispecifics
Paolo Ghia • 8 Dec 2025
The RT1 trial of tislelizumab plus zanubrutinib for the treatment of Richter's transformation
1:30
The RT1 trial of tislelizumab plus zanubrutinib for the treatment of Richter's transformation
Paolo Ghia • 7 Dec 2025
Top updates in CLL from ASH 2025: insights into time-limited treatment from the CLL17 trial
0:53
Top updates in CLL from ASH 2025: insights into time-limited treatment from the CLL17 trial
Paolo Ghia • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals